Replies to post #170422 on Avid Bioservices Inc (CDMO)

[ImaPseudonym]

Might want to check the date. March options expired over a week ago. ;)

[EYEBUYSTOX]

Chenzo, March options expired last week. Always the day after the 3rd Friday of the month. I was just messing with you.

And with regards to ECYT, I wasn't simply picking another stock out of the blue, my friend. They are currently in a phase 3 trial in NSCLC in combination with Docetaxel.

Endocyte is a biotech that announced a partnership with MRK with an up front payment of 120 million and milestones up to $1B. They were able to negotiate that from a cash position of less than $25 million.

Here's what the company said about its lung cancer drug:

Studies also showed that combining vintafolide, whose brand name is Vynfinit, with chemotherapy reduced the risk of death from or a worsening of non-small cell lung cancer by 25 percent, compared with chemotherapy alone.

Detailed trial results, including data regarding overall survival (OS), will be presented at an upcoming medical conference.

I'm not holding my breath on that one, if it ever happens.

http://investor.endocyte.com/releasedetail.cfm?releaseid=834444

So, no survival data has been published in that study...all speculation. And why they wanted it out in the public domain now is probably for the same reason Eli Lilly put out a vague PR about Ramu without disclosing the data. They're trying to get ahead of the bavi data IMO.

So if a company with a drug that only increases progression free survival, an inferior endpoint to overall survival, is able to negotiate a billion dollar deal with $25 million in the bank you can see why there was a sense of urgency to discredit bavituximab which improved overall survival so well. Billions at stake. So, I guess time will tell if we were all played or if the data finally justifies the money needed to advance the platform. Considering PPHM probably has close to $90 million in the bank now, I'm eager to see the terms they're able to negotiate.